🔗 Share this article

While the United States undertakes historic adjustments to its vaccine guidelines, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, a Danish American physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the pandemic and has zeroed in on possible fatalities following Covid vaccination in her recent position at the Food and Drug Administration.

Scheduled Shifts to Pediatric Immunization Schedule

Health officials planned to reveal radical revisions to the childhood vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a significant shift that would put the US out of step with a large portion of the international standard with little proof for public health gain. The announcement has been postponed until the next year.

In place of Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to head the division this calendar year.

A Shift at the Regulatory Body

The acting appointment could signify a closer partnership between the drug and vaccine divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a renewed priority upon reevaluating long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting specific pediatric shot schedules in the US in order to be more like the Danish model, a country with universal health coverage and a number of inhabitants approximately the population of Wisconsin’s.

So far public appearances, she has continued to focus on vaccination policy – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent experience in pharmaceutical research, regulation or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the commissioner and CBER since spring.

“She doesn’t seem to have the requisite experience” for overseeing the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former commissioners of CBER would “grasp laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who led the center have had.”

The drug center has an enormous range of responsibilities at the agency, the former commissioner stated.

“Everybody just zeroes in on the new drug program, but the generic program clears thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, over-the-counter program and more, and every single one have to be supervised,” she noted. “The area you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a significant administrative element to the position, which oversees more than 5,000 personnel. “It’s a huge management job, if you execute it properly,” the former official said.

Response and Contentious Policies

Regarding concerns about Dr. Høeg's credentials and whether this selection indicates increased cooperation among agency officials on immunizations, a representative stated that the “concerns rely on incorrect premises”.

“Her resume matches the responsibilities of her role,” the representative stated, pointing to the months Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computational safety modeling and immunization monitoring”.

As the temporary head, Høeg assumes responsibility for the commissioner’s recently launched expedited review system, a contentious expedited therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being picked for this expedited pathway? Who is making the choices?” Howard said. “There is a lot of confidentiality going on at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent oversight of most medications, with the exception of shots.”

Established History on Vaccines

With immunizations, Høeg has a more documented, if problematic, track record, some experts said. She authored a study using unverified volunteer-provided data to assess the rate of heart inflammation after Covid vaccination. She counseled the state of Florida top health official Joseph Ladapo, who reportedly have altered data to indicate COVID-19 vaccines are more dangerous than they are.

Included in her “wish list” for the new administration encompassed altering regulations for novel immunizations and discontinuing “non-essential” vaccines, she stated after the election on a audio program. At the FDA, Høeg has according to sources suggested preventing young men from obtaining Covid vaccinations.

“She’s an complete dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the data in a highly disingenuous, dishonest way,” Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg joined fellow skeptics, {like|